ReviewFrontiers in immunology2018
Alternative Splicing of FOXP3-Virtue and Vice.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 66 citations in OpenAlex.
- Tumor cell-specific exon 3-deleted FOXP3 isoform promotes growth and metastasis via STAT3 in non-small cell lung cancer.Life medicine · 2026Article
- SRSF3 determines TScience advances · 2026Article
- MAP4K2 suppresses antitumor immunity in a pancreatic cancer model by promoting Treg differentiation.The Journal of clinical investigation · 2026Article
- Review
- Evaluation ofCurrent protein & peptide science · 2026Article
- Reprogramming intratumoral TScience immunology · 2025Article
- Clinical Relevance ofInternational journal of molecular sciences · 2025Article
- Full-Length Transcriptome Sequencing Reveals Treg-Specific Isoform Expression upon Activation.International journal of molecular sciences · 2025Article
- Review
- CD4Science advances · 2025Article
- A splice of life: the discovery, function, and clinical implications of FOXP3 isoforms in autoimmune disease.International immunology · 2024Review
- Deciphering the role of protein kinase A in the control of FoxP3 expression in regulatory T cells in health and autoimmunity.Scientific reports · 2024Article
- Genetic and Epigenetic Association ofInternational journal of molecular sciences · 2024Article
- FOXP3 splice variant expression in males and females in healthy populations and in kidney transplant recipients.Scientific reports · 2024Article
- Regulatory T cells: Supporting lung homeostasis and promoting resolution and repair after lung injury.The international journal of biochemistry & cell biology · 2024Review
- Characterization of the MT-2 Treg-like cell line in the presence and absence of forkhead box P3 (FOXP3).Immunology and cell biology · 2024Article
- SpliceProt 2.0: A Sequence Repository of Human, Mouse, and Rat Proteoforms.International journal of molecular sciences · 2024Article
- FOXP3 full length splice variant is associated with kidney allograft tolerance.Frontiers in immunology · 2024Article
- Assessing TGF-β Prognostic Model Predictions for Chemotherapy Response and Oncogenic Role of FKBP1A in Liver Cancer.Current pharmaceutical design · 2024Article
- Non-canonical NFKB signaling endows suppressive function through FOXP3-dependent regulatory T cell program.Heliyon · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FOXP3 is the lineage-defining transcription factor of CD4+ CD25+ regulatory T cells. While many aspects of its regulation, interaction, and function are conserved among species, alternatively spliced FOXP3 isoforms are expressed only in human cells. This review summarizes current knowledge about alternative splicing of FOXP3 and the specific functions of FOXP3 isoforms in health and disease. Future perspectives in research and the therapeutic potential of manipulating alternative splicing of FOXP3 are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.